MedTrace Logo

Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia

NCT03697707 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-10-10

No results posted yet for this study

Summary

Phase II study to evaluate safety and efficacy of DCP-001 in patients with AML in CR, and with presence of MRD

Conditions

  • Acute Myeloid Leukemia in Remission

Interventions

BIOLOGICAL

DCP-001

allogeneic dendritic cell vaccine

Sponsors & Collaborators

  • Amsterdam UMC, location VUmc

    collaborator OTHER

  • Mendus

    lead INDUSTRY

Principal Investigators

  • A A van de Loosdrecht, MD, PhD · Amsterdam UMC, location VUmc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-15
Primary Completion
2023-03-31
Completion
2025-12-31

Countries

  • Finland
  • Germany
  • Netherlands
  • Norway
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03697707 on ClinicalTrials.gov